NCT04169009View on ClinicalTrials.gov

Persistence of Protection by Shingrix

PHASE4CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

March 31, 2023

Study Completion Date

June 13, 2024

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Zostavax

Intradermal injection of Zostavax

BIOLOGICAL

Shingrix

Given to subjects in Arm 4 who've never had a herpes zoster vaccine

Trial Locations (1)

80045

Clinical Trials Center at University of Colorado Anschutz Medical Center, Aurora

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Colorado, Denver

OTHER

NCT04169009 - Persistence of Protection by Shingrix | Biotech Hunter | Biotech Hunter